Knuff & Co LLC Buys New Position in Danaher Corporation $DHR

Knuff & Co LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 6,462 shares of the conglomerate’s stock, valued at approximately $1,231,000.

Several other hedge funds also recently made changes to their positions in DHR. Sivia Capital Partners LLC lifted its position in shares of Danaher by 6.3% in the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after purchasing an additional 119 shares in the last quarter. First Trust Advisors LP grew its position in Danaher by 34.5% in the second quarter. First Trust Advisors LP now owns 55,418 shares of the conglomerate’s stock valued at $10,947,000 after purchasing an additional 14,217 shares in the last quarter. Main Street Financial Solutions LLC increased its stake in Danaher by 40.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 3,088 shares of the conglomerate’s stock valued at $610,000 after buying an additional 886 shares during the last quarter. Ieq Capital LLC increased its stake in Danaher by 64.2% in the 2nd quarter. Ieq Capital LLC now owns 75,714 shares of the conglomerate’s stock valued at $14,957,000 after buying an additional 29,592 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its position in Danaher by 30.7% during the 2nd quarter. HUB Investment Partners LLC now owns 1,383 shares of the conglomerate’s stock worth $273,000 after buying an additional 325 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Up 6.2%

Shares of DHR stock opened at $211.92 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The firm’s 50-day moving average is $194.30 and its 200-day moving average is $192.44. The stock has a market cap of $148.98 billion, a price-to-earnings ratio of 37.64, a PEG ratio of 2.49 and a beta of 0.78. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80.

Danaher (NYSE:DHR) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period last year, the business posted $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. Sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Piper Sandler initiated coverage on Danaher in a report on Thursday, June 11th. They issued a “neutral” rating and a $200.00 price objective for the company. Argus dropped their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. HSBC lowered their price target on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Wall Street Zen cut Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.